Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07537738) titled 'Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia' on April 7.
Study Type: Observational
Primary Sponsor: Peking University People's Hospital
Condition:
Acute Myeloid Leukemia (AML)
MLL Rearrangement
Intervention:
Diagnostic Test: Detection of leukemia stem cell using multiparameter flow cytometry
Recruitment Status: Recruiting
Date of First Enrollment: June 1, 2025
Target Sample Size: 210
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07537738
Disclaimer: Curated by HT Syndication....